Skip to main content
. 2018 Dec 22;14:424–437. doi: 10.1016/j.omtn.2018.12.010

Figure 1.

Figure 1

AntagomiR-103 and -107 Impair Cardiac Function and Strain

(A) Timeline of the study. A, antagomiR-103 and -107. (B) Analysis of fasted plasma at week 3 of glucose, free fatty acids (FFAs), and triglycerides. (C) Echocardiographic fractional shortening (FS). (D) Schematic representation of the strain analysis, depicting the short-axis view of the left ventricle divided in the analyzed segments and indicating the radial and circumferential axes of motion. (E) Echocardiographic radial and circumferential strain and strain rate metrics. (F–H) Quantification and representative pictures of (F) laminin staining, indicating mean cardiomyocyte area (scale bar, 20 μm); (G) lectin staining, indicating capillary density (scale bar, 20 μm); and (H) picrosirius red staining, indicating fibrosis (scale bar, 1 mm). Scr, scrambled (40 mg/kg/day); Ant, antagomiR (20 mg/kg/day antagomiR-103 and 20 mg/kg/day antagomiR-107). Data are presented as mean ± SEM; n = 7 per group; *p < 0.05 versus scrambled; **p<0.01 versus scrambled; $p<0.05 and p=x versus same treatment at day 1.